论文部分内容阅读
目的探讨单核细胞趋化因子(MCP-1)、环氧合酶-2(COX-2)、过氧化物酶增殖物激活受体y(PPARy)、人类乳头瘤病毒(HPV)在宫颈上皮内瘤变(CIN)中的应用。方法用原位杂交技术检测HPV(主要是HR-HPV)及免疫组化法检测MPC-1、COX-2、PPARy在27例宫颈癌(CC)、36例低级别上皮内瘤变(LSIL)、46例高级别上皮内瘤变(HSIL)、40例对照组(AA)阳性表达情况。结果 1 MCP-1在AA、LSIL、HSIL中阳性率分别为77.50%、30.56%、6.52%,相互间差异有统计学意义(P<0.01);2 COX-2、PPARy在AA、LSIL、HSIL、CC中阳性率分别为0、47.22%、84.78%、92.59%和0、47.22%、60.87%、77.78%;HR-HPV在AA、LSIL、HSIL和CC中的阳性率分别为0、44.44%、76.09%、92.59%。对照组与各组间阳性表达差异有统计学意义(P<0.01)。结论 MCP-1、COX-2、PPARy在宫颈早期病变的发生发展中起重要作用,MCP-1、COX-2、PPARy联合HPV检测可作为准确诊断CIN的指标。
Objective To investigate the effects of monocyte chemotactic factor (MCP-1), cyclooxygenase-2 (COX-2), peroxisome proliferator-activated receptor y (PPARy), human papillomavirus Application of neoplasia (CIN). Methods The expression of MPC-1, COX-2 and PPARy in 27 cases of cervical cancer (CC) and 36 cases of low grade intraepithelial neoplasia (LSIL) were detected by in situ hybridization (HR-HPV) , 46 cases of high-grade intraepithelial neoplasia (HSIL), 40 cases of control group (AA) positive expression. The positive rates of MCP-1 in AA, LSIL and HSIL were 77.50%, 30.56% and 6.52%, respectively, with statistical significance (P <0.01). The expressions of COX-2 and PPARy in AA, LSIL and HSIL The positive rates of HR-HPV in AA, LSIL, HSIL and CC were 0,47.22%, 84.78%, 92.59% and 0,47.22%, 60.87% and 77.78% , 76.09%, 92.59%. There was significant difference between the control group and each group (P <0.01). Conclusions MCP-1, COX-2 and PPARy play an important role in the development of early cervical lesions. The detection of MCP-1, COX-2 and PPARy together with HPV can be used as an accurate indicator of CIN.